In contrast, among melanoma patients (n = 29) receiving various aPD-1 combination therapies, the levels of HVEM+CD8+ T and CD69+CD8+ T cells at three months post-treatment were significantly negatively correlated with PFS [105]. The gene discussed is CD8A; the disease is melanoma.